Whole Human Genome Oligo Microarray Analysis of the Peripheral Blood Mononuclear Cells of Patients With Rheumatoid Arthritis During Different Forms of Anti-Tumor Necrosis-Alpha Treatments.

Trial Profile

Whole Human Genome Oligo Microarray Analysis of the Peripheral Blood Mononuclear Cells of Patients With Rheumatoid Arthritis During Different Forms of Anti-Tumor Necrosis-Alpha Treatments.

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 29 Jul 2014

At a glance

  • Drugs Infliximab (Primary) ; Adalimumab; Etanercept
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors Schering-Plough
  • Most Recent Events

    • 24 Nov 2008 Status changed from not yet recruiting to withdrawn prior to recruitment, reported by ClinicalTrials.gov.
    • 19 Aug 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top